Real Stories.
Enhance your knowledge about heart failure treatment through this series of real world cases. Each case highlights a different aspect in HF management and can help you take better decisions for your patients.
De novo acute decompensated heart failure
Explore a real de novo ADHF case and understand how the introduction of GDMT like sacubitril/valsartan during hospitalization can help reduce the risk of mortality and rehospitalization.
Worsening heart failure symptoms
Worsening heart failure is associated with high risk of adverse outcomes. This real case can help you understand the role of sacubitril/valsartan in reducing HF symptoms, thereby lowering the risk of CV death and all-cause mortality.
Early diagnosis of heart failure
About 80% heart failure patients remain undiagnosed. This real case helps you understand how early diagnosis can offer an opportunity to prescribe effective pharmacological interventions like sacubitril/valsartan that may delay HF progression.
History of hospitalization: Increased vulnerability in patients with heart failure
In patients with heart failure, the post-discharge period is often called the ‘vulnerable phase’. This real case highlights how the optimal use of sacubitril/valsartan can help improve outcomes after discharge.
Diabetes Mellitus: Not just a bystander with HF
Patients with DM have over twice the risk of developing HF than patients without DM. This real case throws light on improved outcomes with sacubitril/valsartan in a high-risk population.
Heart failure and Dilated Cardiomyopathy
This real case helps you understand how sacubitril/valsartan improves QoL, NYHA functional class and 6-MWT, ECHO parameters, and reduces the risk of CV death or hospitalisation in patients with HF & DCM.
The plethora of co-morbidities with HF
The presence of co-morbidities in HF is associated with a poor prognosis. This case explains the importance of implementing the right therapy to reduce mortality in HFrEF patients with co-morbidities.
Renal dysfunction with HF
This real case can help you understand how to implement therapy at the right dose to improve survival and reduce hospitalization in HFrEF patients with WRF.
Heart failure and Hypertension
Hypertension is a major risk factor for the incidence and progression of HF. This case highlights the role of sacubitril/valsartan to reduce the risk of CV death and hospitalization.
Managing Mitral Regurgitation in HF
Explore a case of FMR in HF and understand how GDMT like sacubitril/valsartan improves LVEF and reduces regurgitant volume, ESV, EDV and EDVI.